The ascending pathophysiology of cholestatic liver disease

Hepatology

Volumn 65, Issue 2, 2017, Pages 722-738

  Jansen, Peter L M ^a,b,c   Ghallab, Ahmed ^c,d,e   Vartak, Nachiket ^c,d   Reif, Raymond ^c,d   Schaap, Frank G ^b   Hampe, Jochen ^c,f   Hengstler, Jan G ^c,d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Research Network of Liver Systems Medicine   (Germany)

^d LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^e South Valley University   (Egypt)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICHOLELITHIASIS AGENT; ANTIINFLAMMATORY AGENT; BILE SALT; BIOLOGICAL MARKER; CHOLESTEROL 7ALPHA MONOOXYGENASE; HORMONE RECEPTOR STIMULATING AGENT; ANTIINFECTIVE AGENT; BILE ACID;

ADAPTATION; ANATOMICAL CONCEPTS; BILE CANALICULUS; BILE DUCT; BILE DUCT PRESSURE; BILE LEAKAGE; CHOLANGITIS; CHOLESTASIS; DISEASE COURSE; GALLBLADDER; HUMAN; LIVER CELL; LIVER PARENCHYMA; LIVER TOXICITY; MEDICATION THERAPY MANAGEMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY BILIARY CHOLANGITIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; BLOOD; CHOLANGITIS, SCLEROSING; LIVER DISEASES; MOUSE; PATHOLOGY; PROGNOSIS;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BILE ACIDS AND SALTS; BILE DUCTS; BIOMARKERS; CHOLANGITIS, SCLEROSING; CHOLESTASIS; DISEASE PROGRESSION; HUMANS; LIVER DISEASES; MICE; PROGNOSIS;

EID: 85010383234     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28965     Document Type: Review

References (107)

1. Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001;120:1459-1467.
2. Pollheimer MJ, Fickert P, Stieger B. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis. Mol Aspects Med 2014;37:35-56.
3. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 2016;48:510-518.
4. Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, et al. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat Commun 2015;6:8019.
5. Goyette P, Boucher G, Mallon D, Ellinghaus E, Jostins L, Huang H, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 2015;47:172-179.
6. Chu H, Khosravi A, Kusumawardhani IP, Kwon AH, Vasconcelos AC, Cunha LD, et al. Gene–microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science 2016;352:1116-1120.
7. Navaneethan U. Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf) 2014;2:193-200.
8. Liaskou E, Jeffery LE, Trivedi PJ, Reynolds GM, Suresh S, Bruns T, et al. Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterology 2014;147:221-232.
9. Hofmann AF, Hagey LR. Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 2008;65:2461-2483.
10. Roda A, Hofmann AF, Mysels KJ. The influence of bile salt structure on self-association in aqueous solutions. J Biol Chem 1983;258:6362-6370.
11. Chen W, Owsley E, Yang Y, Stroup D, Chiang JY. Nuclear receptor–mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids. J Lipid Res 2001;42:1402-1412.
12. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011;178:175-186.
13. Schoemaker MH, Conde de la Rosa L, Buist-Homan M, Vrenken TE, Havinga R, Poelstra K, et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid–induced apoptosis via activation of survival pathways. Hepatology 2004;39:1563-1573.
14. Coleman R, Iqbal S, Godfrey PP, Billington D. Membranes and bile formation. Composition of several mammalian biles and their membrane-damaging properties. Biochem J 1979;178:201-208.
15. Puglielli L, Amigo L, Arrese M, Nunez L, Rigotti A, Garrido J, et al. Protective role of biliary cholesterol and phospholipid lamellae against bile acid–induced cell damage. Gastroenterology 1994;107:244-254.
16. Hyogo H, Tazuma S, Nishioka T, Ochi H, Yamaguchi A, Numata Y, et al. Phospholipid alterations in hepatocyte membranes and transporter protein changes in cholestatic rat model. Dig Dis Sci 2001;46:2089-2097.
17. Coleman R, Lowe PJ, Billington D. Membrane lipid composition and susceptibility to bile salt damage. Biochim Biophys Acta 1980;599:294-300.
18. Woolbright BL, Dorko K, Antoine DJ, Clarke JI, Gholami P, Li F, et al. Bile acid–induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis. Toxicol Appl Pharmacol 2015;283:168-177.
19. Zhang Y, Hong JY, Rockwell CE, Copple BL, Jaeschke H, Klaassen CD. Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int 2012;32:58-69.
20. Fickert P, Pollheimer MJ, Beuers U, Lackner C, Hirschfield G, Housset C, et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol 2014;60:1290-1303.
21. Masyuk TV, Ritman EL, LaRusso NF. Quantitative assessment of the rat intrahepatic biliary system by three-dimensional reconstruction. Am J Pathol 2001;158:2079-2088.
22. Strazzabosco M. New insights into cholangiocyte physiology. J Hepatol 1997;27:945-952.
23. Vartak N, Damle-Vartak A, Richter B, Dirsch O, Dahmen U, Hammad S, et al. Cholestasis-induced adaptive remodeling of interlobular bile ducts. Hepatology 2016;63:951-964.
24. Xia X, Francis H, Glaser S, Alpini G, LeSage G. Bile acid interactions with cholangiocytes. World J Gastroenterol 2006;12:3553-3563.
25. Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007;1773:283-308.
26. Slitt AL, Allen K, Morrone J, Aleksunes LM, Chen C, Maher JM, et al. Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. Biochim Biophys Acta 2007;1768:637-647.
27. Schaffner F, Popper H, Perez V. Changes in bile canaliculi produced by norethandrolone: electron microscopic study of human and rat liver. J Lab Clin Med 1960;56:623-628.
28. Das A, Yaqoob U, Mehta D, Shah VH. FXR promotes endothelial cell motility through coordinated regulation of FAK and MMP-9. Arterioscler Thromb Vasc Biol 2009;29:562-570.
29. Liu X, Zhang X, Ji L, Gu J, Zhou M, Chen S. Farnesoid X receptor associates with beta-catenin and inhibits its activity in hepatocellular carcinoma. Oncotarget 2015;6:4226-4238.
30. Porat-Shliom N, Tietgens AJ, Van Itallie CM, Vitale-Cross L, Jarnik M, Harding OJ, et al. Liver kinase B1 regulates hepatocellular tight junction distribution and function in vivo. Hepatology 2016;64:1317-1329.
31. Rodgers LS, Fanning AS. Regulation of epithelial permeability by the actin cytoskeleton. Cytoskeleton (Hoboken) 2011;68:653-660.
32. Yeh TH, Krauland L, Singh V, Zou B, Devaraj P, Stolz DB, et al. Liver-specific beta-catenin knockout mice have bile canalicular abnormalities, bile secretory defect, and intrahepatic cholestasis. Hepatology 2010;52:1410-1419.
33. Sharanek A, Burban A, Burbank M, Le Guevel R, Li R, Guillouzo A, et al. Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs. Sci Rep 2016;6:24709.
34. Reif R, Karlsson J, Gunther G, Beattie L, Wrangborg D, Hammad S, et al. Bile canalicular dynamics in hepatocyte sandwich cultures. Arch Toxicol 2015;89:1861-1870.
35. Jones AL, Hradek GT, Schmucker DL, Underdown BJ. The fate of polymeric and secretory immunoglobulin A after retrograde infusion into the common bile duct in rats. Hepatology 1984;4:1173-1183.
36. Watanabe N, Kojima S, Takashimizu S, Nishizaki Y, Kagawa T, Phillips MJ. Initial site of bile regurgitation following extrahepatic biliary obstruction in living rats. J Gastroenterol Hepatol 2007;22:1983-1992.
37. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997;390:632-636.
38. Gohlke H, Schmitz B, Sommerfeld A, Reinehr R, Haussinger D. α5 β1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes. Hepatology 2013;57:1117-1129.
39. Beuers U. β1 integrin is a long-sought sensor for tauroursodeoxycholic acid. Hepatology 2013;57:867-869.
40. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-225.
41. Lundasen T, Galman C, Angelin B, Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006;260:530-536.
42. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009;49:1228-1235.
43. Zollner G, Fickert P, Zenz R, Fuchsbichler A, Stumptner C, Kenner L, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 2001;33:633-646.
44. –/– mice against cholestatic liver injury. J Hepatol 2016;66:95-101.
45. Torok NJ, Larusso EM, McNiven MA. Alterations in vesicle transport and cell polarity in rat hepatocytes subjected to mechanical or chemical cholestasis. Gastroenterology 2001;121:1176-1184.
46. de Waart DR, Hausler S, Vlaming ML, Kunne C, Hanggi E, Gruss HJ, et al. Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein. J Pharmacol Exp Ther 2010;334:78-86.
47. Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 2013;58:155-168.
48. Harnoss JC, Heidecke CD, Vollmar B, Eipel C. In vivo. imaging of bile accumulation and biliary infarction after common bile duct ligation in rats. Eur Surg Res 2011;47:240-247.
49. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123:1238-1251.
50. Fickert P, Pollheimer MJ, Silbert D, Moustafa T, Halilbasic E, Krones E, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013;58:1201-1208.
51. Elias E, Iqbal S, Knutton S, Hickey A, Coleman R. Increased tight junction permeability: a possible mechanism of oestrogen cholestasis. Eur J Clin Invest 1983;13:383-390.
52. Zhao ZS, Shibamoto T, Tsutsumi M, Cui S, Zhang WM, Takano H, et al. Mouse hepatic portal venoconstrictive response to vasoconstrictors is much weaker than that in rat. J Cardiovasc Pharmacol 2009;54:421-426.
53. Xie C, Wei W, Zhang T, Dirsch O, Dahmen U. Monitoring of systemic and hepatic hemodynamic parameters in mice. J Vis Exp 2014:e51955.
54. Yonemura S, Wada Y, Watanabe T, Nagafuchi A, Shibata M. Alpha-catenin as a tension transducer that induces adherens junction development. Nat Cell Biol 2010;12:533-542.
55. Jensen KH, Lee J, Bohr T, Bruus H, Holbrook NM, Zwieniecki MA. Optimality of the Munch mechanism for translocation of sugars in plants. J R Soc Interface 2011;8:1155-1165.
56. Gin E, Tanaka EM, Brusch L. A model for cyst lumen expansion and size regulation via fluid secretion. J Theor Biol 2010;264:1077-1088.
57. Chara O, Brusch L. Mathematical modelling of fluid transport and its regulation at multiple scales. Biosystems 2015;130:1-10.
58. 2+ and cAMP signaling. Gastroenterology 2006;131:911-920.
59. Rao RK, Samak G. Bile duct epithelial tight junctions and barrier function. Tissue Barriers 2013;1:e25718.
60. Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, et al. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. Hepatology 2000;31:1285-1295.
61. Lunder AK, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology 2016;151:660-669.
62. de Vries EM, Wang J, Leeflang MM, Boonstra K, Weersma RK, Beuers U, et al. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and one year later: evaluation of prognostic value. Liver Int 2016;36:1867-1875.
63. Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res 2003;44:859-866.
64. Zweers SJ de Vries EM, Lenicek M, Tolenaars D, de Waart DR, Koelfat KVK, et al. Prolonged serum fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after oral chenodeoxycholic acid challenge. Hepatol Int 2016; doi:10.1007/s12072-016-9766-x.
65. Zweers SJ, Shiryaev A, Komuta M, Vesterhus M, Hov JR, Perugorria MJ, et al. Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis. Liver Int 2016;36:1370-1377.
66. Friedrich K, Smit M, Brune M, Giese T, Rupp C, Wannhoff A, et al. CD14 is associated with biliary stricture formation. Hepatology 2016;64:843-852.
67. + B-cell receptor clones distinguish immunoglobulin G4–related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology 2016;64:501-507.
68. Sorensen M, Munk OL, Orntoft NW, Frisch K, Andersen KJ, Mortensen FV, et al. Hepatobiliary secretion kinetics of conjugated bile acids measured in pigs by 11C-cholylsarcosine PET. J Nucl Med 2016;57:961-966.
69. Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015;62(1 Suppl.):S25-S37.
70. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342-1347.
71. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-814.
72. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631-643.
73. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015;148:751-761.
74. Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, Rudi de Waart D, et al. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 2006;44:195-204.
75. Klomp LW, Bull LN, Knisely AS, van Der Doelen MA, Juijn JA, Berger R, et al. A missense mutation in FIC1 is associated with greenland familial cholestasis. Hepatology 2000;32:1337-1341.
76. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998;20:233-238.
77. Jansen PLM, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld G, et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 1999;117:1370-1379.
78. Sinke RJ, Carlton VE, Juijn JA, Delhaas T, Bull L, van Berge Henegouwen GP, et al. Benign recurrent intrahepatic cholestasis (BRIC): evidence of genetic heterogeneity and delimitation of the BRIC locus to a 7-cM interval between D18S69 and D18S64. Hum Genet 1997;100:382-387.
79. van Mil SW, van der Woerd WL, van der Brugge G, Sturm E, Jansen PL, Bull LN, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004;127:379-384.
80. Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999;353:210-211.
81. Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004;14:91-102.
82. Painter JN, Savander M, Ropponen A, Nupponen N, Riikonen S, Ylikorkala O, et al. Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur J Hum Genet 2005;13:435-439.
83. Vaz FM, Paulusma CC, Huidekoper H, de Ru M, Lim C, Koster J, et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology 2015;61:260-267.
84. Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, et al. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996;23:904-908.
85. Trauner M, Halilbasic E, Claudel T, Steinacher D, Fuchs C, Moustafa T, et al. Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig Dis 2015;33:433-439.
86. Uriz M, Saez E, Prieto J, Medina JF, Banales JM. Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. PLoS One 2011;6:e28717.
87. 3 output. Hepatology 2011;54:1303-1312.
88. Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DE. Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score. Dig Dis Sci 2016;61:3037-3044.
89. Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, et al. Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol 2010;45:758-762.
90. Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One 2016;11:e0158156.
91. Liaskou E, Karikoski M, Reynolds GM, Lalor PF, Weston CJ, Pullen N, et al. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. Hepatology 2011;53:661-672.
92. Tanaka H, Yang GX, Iwakoshi N, Knechtle SJ, Kawata K, Tsuneyama K, et al. Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clin Exp Immunol 2013;174:364-371.
93. Dhirapong A, Yang GX, Nadler S, Zhang W, Tsuneyama K, Leung P, et al. Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology 2013;57:708-715.
94. Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 2016;63:914-929.
95. Miethke AG, Zhang W, Simmons J, Taylor AE, Shi T, Shanmukhappa SK, et al. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology 2016;63:512-523.
96. Baghdasaryan A, Fuchs CD, Osterreicher CH, Lemberger UJ, Halilbasic E, Pahlman I, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol 2016;64:674-681.
97. Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Richards D, Storey J, et al. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMC Gastroenterol 2016;16:71.
98. +–taurocholate cotransporting polypeptide knockout mice. Hepatology 2015;62:207-219.
99. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis—a pilot study. Aliment Pharmacol Ther 2013;37:604-612.
100. Meissner EG, McLaughlin M, Matthews L, Gharib AM, Wood BJ, Levy E, et al. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int 2016;36:1783-1792.
101. Trottier J, Bialek A, Caron P, Straka RJ, Heathcote J, Milkiewicz P, et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis 2012;44:303-310.
102. Kullak-Ublick GA, Stieger B, Hagenbuch B, Meier PJ. Hepatic transport of bile salts. Semin Liver Dis 2000;20:273-292.
103. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998;273:10046-10050.
104. Axelson M, Aly A, Sjovall J. Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man. FEBS Lett 1988;239:324-328.
105. Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch 2004;447:566-570.
106. Dawson PA, Hubbert M, Haywood J, Craddock AL, Zerangue N, Christian WV, et al. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J Biol Chem 2005;280:6960-6968.
107. Wachsmuth M, Waldeck W, Langowski J. Anomalous diffusion of fluorescent probes inside living cell nuclei investigated by spatially-resolved fluorescence correlation spectroscopy. J Mol Biol 2000;298:677-689.